204 related articles for article (PubMed ID: 31799437)
1. Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53.
Ghaleb A; Yallowitz A; Marchenko N
Commun Biol; 2019; 2():436. PubMed ID: 31799437
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
Ghaleb A; Padellan M; Marchenko N
Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
[TBL] [Abstract][Full Text] [Related]
3. Low-dose but not high-dose γ-irradiation elicits the dominant-negative effect of mutant p53 in vivo.
Ghaleb A; Roa L; Marchenko N
Cancer Lett; 2022 Apr; 530():128-141. PubMed ID: 35065238
[TBL] [Abstract][Full Text] [Related]
4. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
[TBL] [Abstract][Full Text] [Related]
5. Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity.
Isermann T; Şener ÖÇ; Stender A; Klemke L; Winkler N; Neesse A; Li J; Wegwitz F; Moll UM; Schulz-Heddergott R
Nat Commun; 2021 Jun; 12(1):4019. PubMed ID: 34188043
[TBL] [Abstract][Full Text] [Related]
6. The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele.
Shetzer Y; Kagan S; Koifman G; Sarig R; Kogan-Sakin I; Charni M; Kaufman T; Zapatka M; Molchadsky A; Rivlin N; Dinowitz N; Levin S; Landan G; Goldstein I; Goldfinger N; Pe'er D; Radlwimmer B; Lichter P; Rotter V; Aloni-Grinstein R
Cell Death Differ; 2014 Sep; 21(9):1419-31. PubMed ID: 24832469
[TBL] [Abstract][Full Text] [Related]
7. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
9. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
Valenti F; Ganci F; Fontemaggi G; Sacconi A; Strano S; Blandino G; Di Agostino S
Oncotarget; 2015 Mar; 6(8):5547-66. PubMed ID: 25650659
[TBL] [Abstract][Full Text] [Related]
10. The atypical cyclin-like protein Spy1 overrides p53-mediated tumour suppression and promotes susceptibility to breast tumourigenesis.
Fifield BA; Qemo I; Kirou E; Cardiff RD; Porter LA
Breast Cancer Res; 2019 Dec; 21(1):140. PubMed ID: 31829284
[TBL] [Abstract][Full Text] [Related]
11. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
12. Generation of loss of heterozygosity and its dependency on p53 status in human lymphoblastoid cells.
Honma M
Environ Mol Mutagen; 2005; 45(2-3):162-76. PubMed ID: 15688360
[TBL] [Abstract][Full Text] [Related]
13. ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.
Li D; Marchenko ND
Oncotarget; 2017 Jan; 8(4):5823-5833. PubMed ID: 27791982
[TBL] [Abstract][Full Text] [Related]
14. A DDX31/Mutant-p53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer.
Daizumoto K; Yoshimaru T; Matsushita Y; Fukawa T; Uehara H; Ono M; Komatsu M; Kanayama HO; Katagiri T
Cancer Res; 2018 May; 78(9):2233-2247. PubMed ID: 29440146
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.
Tran TQ; Lowman XH; Reid MA; Mendez-Dorantes C; Pan M; Yang Y; Kong M
Oncogene; 2017 Apr; 36(14):1991-2001. PubMed ID: 27721412
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes.
Teh MT; Gemenetzidis E; Chaplin T; Young BD; Philpott MP
Mol Cancer; 2010 Feb; 9():45. PubMed ID: 20187950
[TBL] [Abstract][Full Text] [Related]
17. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
18. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
19. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
[TBL] [Abstract][Full Text] [Related]
20. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
